Ciprofloxacin/fluocinolone acetonide

Drug Profile

Ciprofloxacin/fluocinolone acetonide

Alternative Names: Cetraxal Comp; Cetraxal Plus; DF277/DF289; DF289/DF277; Duoxal; Fluocinolone acetonide/ciprofloxacin; Infalin Duo; Otixal; Otixal®; Otospon; Otovel; OTOVEL; Ultramicina Plus

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SALVAT
  • Developer Arbor Pharmaceuticals; Pediapharm; SALVAT
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 03 Aug 2017 Chemical structure information added
  • 22 Jul 2017 Salvat initiates enrolment in a phase III trial for Otitis Externa (In infants, In children, In adolescents, In adults) in Spain (Otic) (NCT03196973)
  • 29 Jun 2017 Salvat plans a phase III trial for Otitis Externa (In infants, In children, In adolescents, In adults) in Spain, in June 2017 (Otic) (NCT03196973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top